Bio-Quant is a wholly owned subsidiary of NexMed and is dedicated to providing Non-GLP in vitro and in vivo pharmacology, pharmacokinetics and toxicology services.
Bio-Quant's continuous success is based on four pillars:
Total Confidentiality
Secrecy is a powerful advantage in the competitive world of drug discovery. Bio-Quant understands and appreciates this concept and before discussing the collaboration and the target of interest, confidentiality agreements are executed between the Company and Bio-Quant.
Detailed Research Plan
Before starting a partnership, Bio-Quant will develop a detailed research plan with the scientists of the potential partner. The plan will be developed once a business agreement is reached with the client. The comprehensive research plan will describe the assay, its development, and the goals of the Lead Compound Discovery project.
Proven Execution
Executing the research plan in an efficacious and timely manner is essential to the success of a project. Bio-Quant's extensive and proven experience in drug discovery and validation provides our clients with the right tools and experience to make the right decisions on advancing drug candidates to IND enabling studies.
Reporting
Detailed and well written reports are essential to the pharmacology and efficacy data submitted as part of an IND package. Although Bio-Quant does not provide GLP services, we strive to work in the spirit of GLP to meet and exceed the high standards required for developing drugs.
Next Step
If you have reached this stage, this suggests that Bio-Quant Discovery can help your company to achieve its goals faster and more efficiently. If you are ready, please contact us to learn more about our capabilities.
www.bio-quant.com
